Page 11234..»

Category Archives: ALS Treatment

Alexion to begin Phase 3 testing on drug to treat ALS – New Haven Register

Posted: January 18, 2020 at 12:48 am

Alexion Pharmaceuticals in New Haven Alexion Pharmaceuticals in New Haven Photo: Hearst Connecticut Media File Alexion Pharmaceuticals in New Haven Alexion Pharmaceuticals in New Haven Alexion to begin Phase 3 testing on drug to treat ALS Officials with Alexion Pharmaceuticals, which has a significant research and development presence in New Haven, announced the company will begin Phase 3 testing of one of its existing drugs for use in treating amyotrophic lateral sclerosis, also known as ALS or Lou Gehrigs disease. The study of the drug Ultomiris in treating ALS will begin before the end of March and take place over a 50-week period and evaluate 350 adults. Continue reading

Posted in ALS Treatment | Comments Off on Alexion to begin Phase 3 testing on drug to treat ALS – New Haven Register

Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease – Associated Press

Posted: at 12:48 am

-- LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinsons disease -- LRRK2 inhibitor DNL151 Phase 1 demonstrated high levels of target and pathway engagement and modulation of lysosomal biomarkers in healthy volunteers and continues in an expanded Phase 1b study in patients with Parkinsons disease -- IND submitted for DNL310 (ETV:IDS) for Hunter syndrome, Denalis first clinical submission for a large molecule therapeutic enabled by its Transport Vehicle platform technology -- CTA approved for DNL343, a small molecule activator of EIF2B for ALS and other neurodegenerative diseases -- RIPK1 inhibitor DNL747 Phase 1b trials in Alzheimers and ALS fully enrolled and open label extension in ALS ongoing with data readouts on track for mid-2020 SOUTH SAN FRANCISCO, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Continue reading

Posted in ALS Treatment | Comments Off on Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease – Associated Press

N.J. karate legend who inspired thousands loses battle with ALS – NJ.com

Posted: at 12:48 am

The pictures in the corridor, just across from the main ball room at Newarks Robert Treat Hotel, captured the martial arts greatness of Kevin Brown Thompson. A Newark native, Thompson mastered three disciplines weapons, forms and fighting and won world championships in each category, an achievement rarely attained. Hes in the Black Belt Hall of Fame, his name and accomplishments listed with legends Bruce Lee and Chuck Norris. Continue reading

Posted in ALS Treatment | Comments Off on N.J. karate legend who inspired thousands loses battle with ALS – NJ.com

Comprehensive Analysis on Prostacyclin Market based on types and application – Technology Magazine

Posted: at 12:48 am

Global Prostacyclin Market Forecast to 2025 is a new research released at Market Study Report and provides information about industry Top Key Players, Countries, Type and Application. This Prostacyclin report also states Company Profile, sales, Prostacyclin Market revenue and price, market share, market growth and gross margin by regions, Strategic recommendations for the new entrants, Market forecasts for a minimum of five years of all the mentioned segments, sub segments and the regional markets. Continue reading

Posted in ALS Treatment | Comments Off on Comprehensive Analysis on Prostacyclin Market based on types and application – Technology Magazine

Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and…

Posted: January 14, 2020 at 9:49 pm

SAN DIEGO--(BUSINESS WIRE)--Neuropore Therapies, Inc. announced today that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34. Continue reading

Posted in ALS Treatment | Comments Off on Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and…

List of Amyotrophic Lateral Sclerosis Medications (5 Compared …

Posted: December 23, 2019 at 7:42 am

Other names: ALS; Lou Gehrig's Disease; Motor Neurone Disease About Amyotrophic Lateral Sclerosis: A disease of the motor nerve cells in the brain and spinal cord, causing progressive loss of motor control. Continue reading

Posted in ALS Treatment | Comments Off on List of Amyotrophic Lateral Sclerosis Medications (5 Compared …

RADICAVA (edaravone)

Posted: at 7:42 am

I agree that I have read this Consent Form and by providing my personal information and clicking SIGN UP FOR UPDATES I understand and agree that Mitsubishi Tanabe Pharma America, Inc. Continue reading

Posted in ALS Treatment | Comments Off on RADICAVA (edaravone)

Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial – Business…

Posted: at 7:42 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the Sean M. Healey & AMG Center for ALS at Mass General today announced that AMX0035 demonstrated a significant treatment benefit for people with ALS in the CENTAUR study. In the study, participants taking AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p Continue reading

Posted in ALS Treatment | Comments Off on Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial – Business…

Christmas in the City thrills homeless families, takes on poignancy with founders ALS diagnosis – The Boston Globe

Posted: at 7:42 am

Wow, its beautiful! said Aylajoy Dufresne, 5, who wore a pink tutu, as she ran to princess Elena of Avalor and hugged her. Elena! I wasnt expecting all this, said her mother, Cassy Dufresne. Continue reading

Posted in ALS Treatment | Comments Off on Christmas in the City thrills homeless families, takes on poignancy with founders ALS diagnosis – The Boston Globe

AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS…

Posted: at 7:42 am

December 23, 2019 02:11 ET | Source: AB Science multilang-release Paris, 23 December 2019, 8.15am New results published in the peer-reviewed journal Glia further support masitinibs potential mode of action in ALS AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication by an international team of researchers of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis (ALS) that further reinforces the rationale for masitinibs potential neuroprotective effect in ALS. The publication, led by researchers from the Institut Pasteur de Montevideo, the University of Alabama at Birmingham (UAB), the Oregon State University (OSU) and the IMAGINE Institute of Paris, is entitled, Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL34, and SCF in amyotrophic lateral sclerosis. Continue reading

Posted in ALS Treatment | Comments Off on AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS…

Page 11234..»